Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Am Vet Med Assoc ; 226(4): 556-61, 2005 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-15742696

RESUMO

OBJECTIVE: To evaluate adrenal sex hormone concentrations in response to ACTH stimulation in healthy dogs, dogs with adrenal tumors, and dogs with pituitary-dependent hyperadrenocorticism (PDH). DESIGN: Prospective study. ANIMALS: 11 healthy control dogs, 9 dogs with adrenal-dependent hyperadrenocorticism (adenocarcinoma [ACA] or other tumor); 11 dogs with PDH, and 6 dogs with noncortisol-secreting adrenal tumors (ATs). PROCEDURE: Hyperadrenocorticism was diagnosed on the basis of clinical signs; physical examination findings; and results of ACTH stimulation test, low-dose dexamethasone suppression test, or both. Dogs with noncortisol-secreting ATs did not have hyperadrenocorticism but had ultrasonographic evidence of an AT. Concentrations of cortisol, androstenedione, estradiol, progesterone, testosterone, and 17-hydroxyprogesterone were measured before and 1 hour after i.m. administration of 0.25 mg of synthetic ACTH. RESULTS: All dogs with ACA, 10 dogs with PDH, and 4 dogs with ATs had 1 or more sex hormone concentrations greater than the reference range after ACTH stimulation. The absolute difference for progesterone, 17-hydroxyprogesterone, and testosterone concentrations (value obtained after ACTH administration minus value obtained before ACTH administration) was significantly greater for dogs with ACA, compared with the other 3 groups. The absolute difference for androstenedione was significantly greater for dogs with ACA, compared with dogs with AT and healthy control dogs. CONCLUSIONS AND CLINICAL RELEVANCE: Dogs with ACA secrete increased concentrations of adrenal sex hormones, compared with dogs with PDH, noncortisol-secreting ATs, and healthy dogs. Dogs with noncortisol-secreting ATs also have increased concentrations of sex hormones. There is great interdog variability in sex hormone concentrations in dogs with ACA after stimulation with ACTH.


Assuntos
Corticosteroides/metabolismo , Neoplasias do Córtex Suprarrenal/veterinária , Hiperfunção Adrenocortical/veterinária , Hormônio Adrenocorticotrópico/metabolismo , Doenças do Cão/metabolismo , Corticosteroides/sangue , Neoplasias do Córtex Suprarrenal/sangue , Neoplasias do Córtex Suprarrenal/metabolismo , Adenoma Adrenocortical/sangue , Adenoma Adrenocortical/metabolismo , Adenoma Adrenocortical/veterinária , Carcinoma Adrenocortical/sangue , Carcinoma Adrenocortical/metabolismo , Carcinoma Adrenocortical/veterinária , Hiperfunção Adrenocortical/sangue , Hiperfunção Adrenocortical/metabolismo , Hormônio Adrenocorticotrópico/sangue , Animais , Dexametasona , Doenças do Cão/sangue , Cães , Feminino , Masculino , Progesterona/sangue , Progesterona/metabolismo , Estudos Prospectivos , Testosterona/sangue , Testosterona/metabolismo
2.
Vet Clin Pathol ; 32(4): 180-7, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-14655102

RESUMO

BACKGROUND: The concentration of canine adrenocorticotropic hormone (ACTH) is usually determined by radioimmunoassay. However, chemiluminescent assay techniques have many advantages for clinical endocrine testing. OBJECTIVES: The objectives of this study were to validate a commercially available chemiluminescent assay for determination of canine ACTH concentration and to determine whether protease inhibitors are appropriate for use in the chemiluminescent assay system. METHODS: Biological specificity was evaluated by treatment of 3 dogs with ovine corticotropin-releasing hormone (CRH) followed by serial measurements of ACTH and by comparison with a previously validated immunoradiometric assay. All samples were collected both in the presence and absence of aprotinin, a protease inhibitor. The assay was further evaluated by measurement of intra-assay precision, interassay precision, and recovery after dilution. RESULTS: Baseline ACTH concentrations ranged from 5.6 to 15.3 pg/mL, and maximum ACTH concentrations of 158 to 1240 pg/mL were observed 30-60 minutes after CRH administration. Plasma samples collected with aprotinin had significantly lower ACTH concentrations than did samples collected without aprotinin. The intra-assay coefficients of variance (CVs) ranged from 4.1 to 8.2%, and interassay CVs ranged from 4.6. to 14.8%. Recovery after dilution with canine plasma ranged from 93.4 to 103.0% of predicted concentration; however, inadequate recovery was observed with other diluents. There was a high correlation with the immunoradiometric assay (r =.925) but a significant negative bias (-32.9, 95% confidence interval -50.8 to -14.9). CONCLUSIONS: This chemiluminescent assay is a valid technique for measurement of ACTH in canine plasma. ACTH concentration measured by chemiluminescence is lower than that measured by immunoradiometry. Aprotinin decreases the measured concentration of ACTH, and this effect should be taken into account when interpreting results. Diluents supplied with the kit should not be used for dilution of canine samples.


Assuntos
Hormônio Adrenocorticotrópico/sangue , Hormônio Liberador da Corticotropina , Cães/sangue , Técnicas Imunoenzimáticas/veterinária , Medições Luminescentes , Animais , Aprotinina/farmacologia , Feminino , Técnicas Imunoenzimáticas/métodos , Técnicas Imunoenzimáticas/normas , Masculino , Radioimunoensaio/métodos , Radioimunoensaio/normas , Radioimunoensaio/veterinária , Valores de Referência , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Inibidores de Serina Proteinase/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...